Evaluation of the effect of crocin on prevention of atrial fibrillation after coronary artery bypass grafting or heart valve replacement: A double-blind, randomized, placebo-controlled trial.
Seyyed Hamed Hashemi Shahri, Ghasem Soltani, Mohammad Abbasi Teshnizi, Aliasghar Moeinipour, Mohammad Tayyebi, Reza Javidi Dasht Bayaz, Farshad Abedi, Vahid Ghavami, Shahram Amini, Amir Hooshang Mohammadpour
{"title":"Evaluation of the effect of crocin on prevention of atrial fibrillation after coronary artery bypass grafting or heart valve replacement: A double-blind, randomized, placebo-controlled trial.","authors":"Seyyed Hamed Hashemi Shahri, Ghasem Soltani, Mohammad Abbasi Teshnizi, Aliasghar Moeinipour, Mohammad Tayyebi, Reza Javidi Dasht Bayaz, Farshad Abedi, Vahid Ghavami, Shahram Amini, Amir Hooshang Mohammadpour","doi":"10.22038/AJP.2022.20908","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate the effect of crocin on the prevention of atrial fibrillation after coronary artery bypass grafting (CABG) and heart valve replacement.</p><p><strong>Materials and methods: </strong>100 patients who were scheduled for CABG or heart valve replacement surgeries were randomly assigned into two groups of treatment and placebo. In the treatment group, patients received crocin tablets from three days prior to surgery and on the first three postoperative days (for a total of six days). During the first three days after surgery, postoperative atrial fibrillation (POAF) was assessed by electrocardiogram monitoring. Prooxidant-antioxidant balance (PAB) and c-reactive protein (CRP) levels were also assessed.</p><p><strong>Results: </strong>POAF developed in 7 patients in the treatment group versus 18 patients in the control (p=0.02). PAB levels were significantly lower in the crocin group (p<0.001), while differences in CRP levels were insignificant (p=0.39).</p><p><strong>Conclusion: </strong>It seems that prophylactic use of crocin is effective in reducing the incidence of POAF in patients undergoing heart surgeries.</p>","PeriodicalId":8677,"journal":{"name":"Avicenna Journal of Phytomedicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768858/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Phytomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/AJP.2022.20908","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study was to evaluate the effect of crocin on the prevention of atrial fibrillation after coronary artery bypass grafting (CABG) and heart valve replacement.
Materials and methods: 100 patients who were scheduled for CABG or heart valve replacement surgeries were randomly assigned into two groups of treatment and placebo. In the treatment group, patients received crocin tablets from three days prior to surgery and on the first three postoperative days (for a total of six days). During the first three days after surgery, postoperative atrial fibrillation (POAF) was assessed by electrocardiogram monitoring. Prooxidant-antioxidant balance (PAB) and c-reactive protein (CRP) levels were also assessed.
Results: POAF developed in 7 patients in the treatment group versus 18 patients in the control (p=0.02). PAB levels were significantly lower in the crocin group (p<0.001), while differences in CRP levels were insignificant (p=0.39).
Conclusion: It seems that prophylactic use of crocin is effective in reducing the incidence of POAF in patients undergoing heart surgeries.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
